ImmunityBio, Inc.

ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen patients’ natural immune system to fight cancer.

[ImmunityBio, Inc. @ImmunityBio]

Early detection can be simple: pay attention to what feels different.

Blood in the urine, a shift in frequency, discomfort that lingers; these signs may seem easy to dismiss,
but recognizing them can expand the opportunity for timely evaluation and improved outcomes.

ImmunityBio's relentless pursuit of groundbreaking therapies underscores our commitment to delivering hope and better solutions for patients with bladder cancer.

[ImmunityBio, Inc. @ImmunityBio]

We’re heading to ASCO 2026.

We’re looking forward to joining researchers, clinicians, advocates, and industry partners united by a shared goal: improving outcomes for people impacted by cancer. Our team values the opportunity to collaborate and continue advancing patient-focused innovation alongside the broader oncology
community.

Visit us at booth #27131 to connect with the ImmunityBio team.

[ImmunityBio, Inc. @ImmunityBio]

Behind every bladder cancer diagnosis is a person navigating uncertainty, complex decisions, and changes to their daily lifestyle. Organizations like @BladderCancerUS help ensure that affected individuals have access to information, support, and a community that understands what they're facing.

Learn more about BCAN's resources for patients and caregivers: https://t.co/v94waPBE2N

[ImmunityBio, Inc. @ImmunityBio]

On Memorial Day, we pause to honor the bravery of those who stepped forward to serve. Your strength, service, and sacrifice will never be forgotten.

[ImmunityBio, Inc. @ImmunityBio]

ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application of its bladder cancer therapy in combination with Bacillus Calmette-Guerin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease without carcinoma in situ.

Learn more: https://t.co/hOT44oIlWV

[ImmunityBio, Inc. @ImmunityBio]

At the heart of every advancement are the people who make it possible.

Our focus is on bringing in individuals who are collaborative, solution-oriented, and motivated by work that carries broader significance. View our open roles: https://t.co/LgB4hHvT2K

[ImmunityBio, Inc. @ImmunityBio]

At #AUA2026, our Founder, Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, took center stage to address several of the most pressing challenges facing the bladder cancer community today: the continued impact of BCG shortages and ImmunityBio's efforts to help advance new supply solutions to the broader need for sustainable innovation across the field.

The discussion reinforced an important reality: progressing bladder cancer care requires more than scientific progress alone. It also demands long-term commitment, collaboration, and practical solutions that help ensure patients can reliably access the therapies they need.

[Amer. Urol. Assn. @AmerUrological]

ImmunityBio Announces Exclusive Supply of Tokyo-172 BCG (ImmunoBladder) to Address 14 Year US Shortage Following Randomized Clinical Trial Comparing Tokyo to TICE Strain.

Learn more here: https://t.co/FAhapwwDmk

@DrPatrick #AUA26

[ImmunityBio, Inc. @ImmunityBio]

ImmunityBio has announced an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the development and commercialization of Tokyo strain BCG in the U.S.

Today's announcement marks a notable step forward in addressing the ongoing BCG shortage that has impacted urologists and bladder cancer patients for more than a decade.

Learn more: https://t.co/99wRn8gns0

[ImmunityBio, Inc. @ImmunityBio]

We are honored to join the urology community at the American Urological Association Annual Meeting as leaders across the field come together to advance the future of bladder cancer care.

At ImmunityBio, our work in the space is centered on exploring immunotherapy approaches for patients who continue to face complex treatment decisions. As new clinical insights and data continue to emerge, we aim to support a patient-centered strategy to care and ongoing conversations around the evolving treatment landscape.

Meaningful progress requires more than scientific innovation alone - it takes continued collaboration across the urology collective, with a shared focus on improving outcomes for patients. #AUA2026

[ImmunityBio, Inc. @ImmunityBio]

Bladder cancer continues to impact tens of thousands of individuals each year. Increasing awareness of the disease - and recognizing changes early - can play an important role in improving outcomes.

ImmunityBio remains committed to supporting the patients, caregivers, and healthcare providers impacted.

[ImmunityBio, Inc. @ImmunityBio]

Bladder cancer remains a persistent challenge in oncology, demanding meaningful innovation.

Through a multi-faceted approach to immunotherapy, ImmunityBio is focused on redefining how this disease is treated - grounded in science, guided by patients, and driven by our mission.

This Bladder Cancer Awareness Month, we recognize the resilience of patients, the support of caregivers, and the guidance of healthcare providers who continue to push progress forward. Learn more about our work: https://t.co/dRcw7BdV2y

[ImmunityBio, Inc. @ImmunityBio]

This weekend, we joined the @BladderCancerUS (BCAN) Walk in Los Angeles, coming together with a community united by strength, resilience, and shared purpose.

Every step reflects the ongoing journey faced by those impacted by bladder cancer and the collective commitment to raising awareness and supporting one another along the way.

Get involved in a walk near you: https://t.co/JCbQkXoQ7g

[ImmunityBio, Inc. @ImmunityBio]

At ImmunityBio, individuals like Hollie Wells-Dorsett play an important role in moving our mission forward. Her commitment to advancing immunotherapy and supporting greater understanding of the immune system is part of what drives progress in cancer care.

[ImmunityBio, Inc. @ImmunityBio]

Access to innovative cancer therapies continues to expand. ANKTIVA® is now available in Saudi Arabia for patients with bladder and lung cancers, marking an important step in ImmunityBio’s global efforts to reach more patients.

Read more: https://t.co/DwjGwcpkp5

[ImmunityBio, Inc. @ImmunityBio]

As we look ahead to the 2026 @BladderCancerUS walks, we're proud to stand alongside the bladder cancer community.

Immunitybio is honored to sponsor these events and be part of the collective effort to raise awareness and support patients and caregivers in their cancer journeys. Register for a walk near you: https://t.co/5EDLHXsYvD

[ImmunityBio, Inc. @ImmunityBio]

We're sharing our latest update, highlighting year-over-year revenue growth and financial metrics that support continued progress in our broader efforts.

Access the full announcement: https://t.co/dRvxHvWhy9

[ImmunityBio, Inc. @ImmunityBio]

This World Health Day, we're reminded that progress in healthcare requires continued innovation.

Our work centers on developing immune-based approaches designed to address areas of ongoing unmet need in cancer care. View our pipeline: https://t.co/jzMALyPdAl

[ImmunityBio, Inc. @ImmunityBio]

Glioblastoma is not only among the most common malignant brain tumors - it is also one of the most aggressive and difficult to treat.

Advancing care requires new approaches.

Learn more about how we are exploring the potential of the immune system to enhance how the body identifies and responds to cancers such as glioblastoma: https://t.co/OhmYvpAzYb